The use of rabbit intestinal permeability as an in vitro assay in the search for orally active GPIIb/IIIa antagonists

被引:1
|
作者
Samanen, JM
Lee, CP
Smith, PL
Bondinell, WE
Calvo, RR
Jakas, DR
Newlander, KA
Parker, M
Uzinskas, I
Yellin, TO
Nichols, AJ
机构
[1] SMITHKLINE BEECHAM PHARMACEUT,DEPT DRUG DELIVERY,KING OF PRUSSIA,PA 19406
[2] SMITHKLINE BEECHAM PHARMACEUT,DEPT PHARMACOL,KING OF PRUSSIA,PA 19406
关键词
absorption; peptides; transport; permeability; pharmacophore model; GPIIb/IIIa antagonists; oral activity; bioavailability; Ussing Chamber;
D O I
10.1016/S0169-409X(96)00431-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A series of potent, high affinity GPIIb/IIIa antagonists were evaluated for intestinal permeability in vitro using rabbit intestinal strips mounted in the Ussing Chamber. In this series of compounds, structural modifications were found to impact intestinal permeability. In general, modifications that would contribute to lipophilicity (e.g. olefinic replacement for amide, phenethyl or isopropyl for methyl) did not enhance permeability. When these intestinal permeabilities were compared to mannitol, which displays similar to 20% oral bioavailability in humans (Laker et al. (1982) fur. J. Clin. Invest. 12, 485-491), it was possible then to select compounds with permeabilities comparable to mannitol for oral (intraduodenal) evaluation in conscious dogs. The influence of intestinal permeability on oral efficacy can be observed within a series of compounds with closely related structures, but is less discernable in across structural series. Intestinal permeability data can provide meaningful, reliable data that can help in analog design and in the selection of compounds for oral evaluation.
引用
收藏
页码:133 / 142
页数:10
相关论文
共 50 条
  • [1] Orally active isoxazoline GPIIb/IIIa antagonists
    Mousa, SA
    Wityak, J
    CARDIOVASCULAR DRUG REVIEWS, 1998, 16 (01): : 48 - 61
  • [2] Orally active GPIIb/IIIa-receptor antagonists
    Lloyd, AW
    DRUG DISCOVERY TODAY, 2000, 5 (04) : 164 - 165
  • [3] Orally active GPIIb/IIIa-receptor antagonists
    Terrett, N
    DRUG DISCOVERY TODAY, 2000, 5 (05) : 211 - 212
  • [4] A new class of orally active GPIIb-IIIa antagonists.
    Steiner, B
    Alig, L
    Blackburn, B
    Bunting, S
    Hurzeler, M
    Schmitt, M
    Weiss, S
    Weller, T
    BLOOD, 1995, 86 (10) : 351 - 351
  • [5] IN SEARCH OF AN ORALLY-ACTIVE GPIIB/IIIA ANTAGONIST - CYCLIC-PEPTIDES AND BEYOND
    JACKSON, SA
    DEGRADO, WF
    MOUSA, SA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 210 : 117 - ORGN
  • [6] Orbofiban: An orally active GPIIB/IIIa platelet receptor antagonist
    Nicholson, NS
    Abood, NA
    Panzer-Knodle, SG
    Frederick, LG
    Page, JD
    Salyers, AK
    Suleymanov, OD
    Szalony, JA
    Taite, BB
    Anders, RJ
    MEDICINAL RESEARCH REVIEWS, 2001, 21 (03) : 211 - 226
  • [7] Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists
    Samanen, JM
    Ali, FE
    Barton, LS
    Bondinell, WE
    Burgess, JL
    Callahan, JF
    Calvo, RR
    Chen, WT
    Chen, LC
    Erhard, K
    Feuerstein, G
    Heys, R
    Hwang, SM
    Jakas, DR
    Keenan, RM
    Ku, TW
    Kwon, C
    Lee, CP
    Miller, WH
    Newlander, KA
    Nichols, A
    Parker, M
    Peishoff, CE
    Rhodes, G
    Ross, S
    Shu, A
    Simpson, R
    Takata, D
    Yellin, TO
    Uzsinskas, I
    Venslavsky, JW
    Yuan, CK
    Huffman, WF
    JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (25) : 4867 - 4870
  • [8] Effect of antagonists on GPIIb/IIIa receptor occupancy: use of a whole blood flow cytometry assay
    Besson, I
    McGregor, JL
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2711 - P2711
  • [9] The discovery of DMP 753, an orally active isoxazoline GPIIb/IIIa antagonist.
    Olson, RE
    Wityak, J
    Xue, CB
    Sielecki, TM
    Cain, GA
    Mousa, SA
    Thoolen, MJ
    Racanelli, AL
    Hausner, EA
    Reilly, TM
    DeGrado, WF
    Wexler, RR
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 211 : 250 - MEDI
  • [10] Design and synthesis of an orally active GPIIb/IIIa antagonist based on a phenylpiperazine scaffold
    van Maarseveen, JH
    den Hartog, JAJ
    Tipker, K
    Reinders, JH
    Brakkee, J
    Schon, U
    Kehrbach, W
    Kruse, CG
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (12) : 1531 - 1536